These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 18284525

  • 1. Cost-effectiveness analysis of triple test in second-trimester maternal serum screening for Down's syndrome: an experience from Taiwan with decreasing birth rate but increasing population of old pregnant women.
    Hwa HL, Yen MF, Lin CL, Ko TM, Hsieh FJ, Chen TH.
    J Eval Clin Pract; 2008 Apr; 14(2):191-7. PubMed ID: 18284525
    [Abstract] [Full Text] [Related]

  • 2. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome.
    Shackley P, McGuire A, Boyd PA, Dennis J, Fitchett M, Kay J, Roche M, Wood P.
    J Public Health Med; 1993 Jun; 15(2):175-84. PubMed ID: 7688977
    [Abstract] [Full Text] [Related]

  • 3. Prenatal screening for Down's syndrome using inhibin-A as a serum marker.
    Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG.
    Prenat Diagn; 1996 Feb; 16(2):143-53. PubMed ID: 8650125
    [Abstract] [Full Text] [Related]

  • 4. [Evaluation of Down's syndrome screening methods using maternal serum biochemistry in the second trimester pregnancy].
    Yu DY, Fu P, Zhang ZH, Wang F, Han MY, Ren HY, Zhao W, Zhang K, Li S, Jiang N.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Jun; 28(3):332-5. PubMed ID: 21644235
    [Abstract] [Full Text] [Related]

  • 5. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
    Lamlertkittikul S, Chandeying V.
    J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
    [Abstract] [Full Text] [Related]

  • 6. First-trimester Down syndrome screening in women younger than 35 years old and cost-effectiveness analysis in Taiwan population.
    Chou CY, Hsieh FJ, Cheong ML, Lee FK, She BQ, Tsai MS.
    J Eval Clin Pract; 2009 Oct; 15(5):789-96. PubMed ID: 19811590
    [Abstract] [Full Text] [Related]

  • 7. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong.
    Lam YH, Ghosh A, Tang MH, Tang LC, Lee CP, Sin SY, Ho PK.
    Prenat Diagn; 1998 Jun; 18(6):585-89. PubMed ID: 9664604
    [Abstract] [Full Text] [Related]

  • 8. Contingent triple-screening for Down syndrome in the second trimester: a feasibility study in Mainland Chinese population.
    Xie Z, Lu S, Li H.
    Prenat Diagn; 2010 Jan; 30(1):74-6. PubMed ID: 19967750
    [Abstract] [Full Text] [Related]

  • 9. Maternal serum markers for Down's syndrome pregnancies.
    Chew S, Anandakumar C, Ratnam SS.
    Singapore Med J; 1995 Aug; 36(4):417-23. PubMed ID: 8919160
    [Abstract] [Full Text] [Related]

  • 10. [Screening for Down syndrome using triple marker testing in the second trimester of pregnancy].
    Lesin J, Skrablin S, Durić K, Suchanek E, Muzinić D, Kalafatić D, Kuvacić I, Zlopasa G, Plavec A.
    Lijec Vjesn; 2003 Aug; 125(3-4):55-60. PubMed ID: 12899094
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of prenatal diagnosis intervention for Down's syndrome in China.
    Chen Y, Qian X, Li J, Zhang J, Chu A, Schweitzer SO.
    Int J Technol Assess Health Care; 2007 Aug; 23(1):138-45. PubMed ID: 17234028
    [Abstract] [Full Text] [Related]

  • 12. Risk prediction for Down's syndrome in young pregnant women using maternal serum biomarkers: determination of cut-off risk from receiver operating characteristic curve analysis.
    Hwa HL, Ko TM, Hsieh FJ, Yen MF, Chou KP, Chen TH.
    J Eval Clin Pract; 2007 Apr; 13(2):254-8. PubMed ID: 17378872
    [Abstract] [Full Text] [Related]

  • 13. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V, Moatti JP, Muller F, Le Galès C, Boué A.
    Rev Epidemiol Sante Publique; 1993 Apr; 41(1):3-15. PubMed ID: 8465062
    [Abstract] [Full Text] [Related]

  • 14. The evolving national birth prevalence of Down syndrome in Taiwan. A study on the impact of second-trimester maternal serum screening.
    Jou HJ, Kuo YS, Hsu JJ, Shyu MK, Hsieh TT, Hsieh FJ.
    Prenat Diagn; 2005 Aug; 25(8):665-70. PubMed ID: 16049991
    [Abstract] [Full Text] [Related]

  • 15. Antenatal screening for Down's syndrome.
    Wald NJ, Kennard A, Hackshaw A, McGuire A.
    J Med Screen; 1997 Aug; 4(4):181-246. PubMed ID: 9494915
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Second-trimester maternal serum screening for Down's syndrome: free beta-human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol.
    Extermann P, Bischof P, Marguerat P, Mermillod B.
    Hum Reprod; 1998 Jan; 13(1):220-3. PubMed ID: 9512261
    [Abstract] [Full Text] [Related]

  • 18. [Screening by maternal serum markers for Down's syndrome].
    Liu JT, Hao N, Sun NH, Wang FY, Xu YH, Gai MY, Bian XM, Yang JQ.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.